Celfex AB is a wholly owned subsidiary of Swiss based MHG Management GmbH (‘MHG’).  

MHG is is partnered with NOAH Therapeutics (NOAH), a leading Contract Research Organization (CRO) based in India.   

Celfex AB shall proceed with Phase 2 clinical trial of Celfex with NOAH.  

This decision marks a significant milestone in development of Celfex product which is targeting mild to medium Atopic Dermatitis (Eczema).  Celfex is a stable topical formulation of Fexofenadine which already has a known safety profile.  Celfex is expecting rapid clinical progress and will likely be in a position to announce clinical results in 6-9 months.      

John Schnell, CEO of MHG Management GmbH, commented:

“We are proud to have acquired Celfex AB and forged the partnership with NOAH, a well-established CRO with deep expertise in clinical trial management across diverse therapeutic areas. NOAH is linked with Saint Theresa Hospital in India and its leadership team has extensive experience in Western Europe.   NOAH Therapeutics will be instrumental in accelerating our Phase 2 trial under stringent regulatory and ethical standards.”

NOAH will be responsible for full-service CRO operations, including trial site management, patient recruitment, regulatory submission, data management, and clinical monitoring in accordance with ICH-GCP guidelines. The trial is scheduled to begin in Q4 2025 and will focus on evaluating the efficacy and safety profile of Fexofenadine in an expanded patient population.

About Celfex AB
A wholly owned subsidiary (special purpose vehicle) of MHG Management GmbH and based in Sweden (proximate to collaborating strategic partners).  Celfex has been licensed to Celfex AB which is responsible for leading clinical development.  

About NOAH Therapeutics (India)
NOAH Therapeutics is a full-service Contract Research Organization headquartered in D.No.7-1-645, Erragadda, Sanathnagar, Near St Theresa Hospital, Hyderabad, Telangana 500018 India  offering comprehensive clinical research solutions from Phase I to IV, with a focus on operational excellence, data integrity, and regulatory compliance.

Media Contact Email: infoll@mhg.management

Phone: +41 794491158